Avutometinib

Pancreas Cancer

Washington University School of MedicineSmall moleculePhase 2Active

CCC

55/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 73/ 100

Competitive context

81 Active assets in the Pancreas Cancer cohort.

Asset / Sponsor	Phase	Rating
Epirubicin TME Pharma AG	Phase 3	BB
Pembrolizumab Essen Biotech	Phase 2	BB
Surufatinib Tianjin Medical University Cancer Institute and Hospital	Phase 3	BB
Docetaxel Minia University	Phase 3	BB
PANITUMUMAB SWOG Cancer Research Network	Phase 3	BB

View all 50 →

Same molecule, other indications

Avutometinib is also rated in:

KRAS Activating MutationDormant

BB

Indicative ·

69 / 100

ovarian serous adenocarcinomaDormant

BB

Indicative ·

68 / 100

non-small cell lung carcinomaDormant

B

Indicative ·

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.